(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2(Date:9/4/2008)... Patient Identification for Targeted Therapies ...atment HUNTINGTON BEACH, Calif., and AMSTERDAM,...orld leader in molecular cancer diagnostics,today...gnostic test that,allows physicians to quantitativ...trogen receptor (ER), progesterone receptor (PR) a...
(Date:9/3/2008)...pt. 3 /- Simcere,Pharmaceut...nd supplier of,branded generic pharmaceuticals and...product Endu (also known as Endostar) in China,an...cal study., At the request of the SFDA, Simcere i...date the safety and therapeutic efficacy of Endu, ...
(Date:9/3/2008)...and GENEVA, Sept. 3 /- Artelis SA and... based monoclonal antibody,production with the ach...per liter. This record level was accomplished by a...high-performance stable Selexis CHO,production cel...tists at,Selexis SA using their proprietary Selexi...
(Date:9/3/2008)...erations, Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET,...-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV ) anno...ations to focus on commercial and late-stage produ...pecialty pharmaceutical pain management,company. T...
Breaking Medicine Technology:Agendia Launches TargetPrint(R) for Breast Cancer Patients 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Amylin Pharmaceuticals Initiates Phase 2B Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment in Obesity 1975 1Amylin Pharmaceuticals Initiates Phase 2B Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment in Obesity 1975 2Amylin Pharmaceuticals Initiates Phase 2B Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment in Obesity 1975 3Amylin Pharmaceuticals Initiates Phase 2B Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment in Obesity 1975 4Amylin Pharmaceuticals Initiates Phase 2B Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment in Obesity 1975 5eResearchTechnology Reports First Quarter 2008 Results 5107 1eResearchTechnology Reports First Quarter 2008 Results 5107 2eResearchTechnology Reports First Quarter 2008 Results 5107 3eResearchTechnology Reports First Quarter 2008 Results 5107 4eResearchTechnology Reports First Quarter 2008 Results 5107 5eResearchTechnology Reports First Quarter 2008 Results 5107 6eResearchTechnology Reports First Quarter 2008 Results 5107 7eResearchTechnology Reports First Quarter 2008 Results 5107 8eResearchTechnology Reports First Quarter 2008 Results 5107 9Verenium Reports Financial Results for the First Quarter 2008 5104 1Verenium Reports Financial Results for the First Quarter 2008 5104 2Verenium Reports Financial Results for the First Quarter 2008 5104 3Verenium Reports Financial Results for the First Quarter 2008 5104 4Verenium Reports Financial Results for the First Quarter 2008 5104 5Verenium Reports Financial Results for the First Quarter 2008 5104 6Verenium Reports Financial Results for the First Quarter 2008 5104 7Verenium Reports Financial Results for the First Quarter 2008 5104 8Verenium Reports Financial Results for the First Quarter 2008 5104 9Verenium Reports Financial Results for the First Quarter 2008 5104 10Verenium Reports Financial Results for the First Quarter 2008 5104 11Divigel 28R 29 28estradiol gel 29 0 1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated wit 1974 1Divigel 28R 29 28estradiol gel 29 0 1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated wit 1974 2Divigel 28R 29 28estradiol gel 29 0 1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated wit 1974 3... no new stent thrombosis after two years in,high-r...NA, Spain, May 22, 2007,/PRNewswire-FirstCall/ -- ...-year follow-up data from its TAXUS VI clinical,tr...icacy benefits,associated with a moderate-release ...-eluting stent system -- which is not,approved for...
...up analysis shows no stent thrombosis or MACE,afte...y 22, 2007,/PRNewswire-FirstCall/ -- Boston Scient...itional data from the SPIRIT FIRST, II,and III Cli...y data,for the market-leading TAXUS(R) Express2(TM...NCE(TM) V (PROMUS(TM)) Everolimus,Eluting Coronary...
Other Medicine Technology:Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 2SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 3Inquire
Adjustable speed vortex with inter-changeable heads, 110 V
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures.
...e Mo Bio Vortex Adapter in conjunction with the Vo...sing the Mo Bio Vortex Adapter is an inexpensive a...hines which offer the same technology. This parti...one time and will fit any Vortex Genie 2 with a 3 ...
Medicine Products: